Repligen Seeks To Block Launch Of Bristol-Myers Drug
A Massachusetts biotech company has rekindled its battle with Bristol-Myers Squibb over the patent for a new arthritis drug, which the global pharmaceutical company plans to launch next month....To view the full article, register now.
Already a subscriber? Click here to view full article